Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOB | P04114 | 16/20 | 0.60 |
| ▸ | MTTP | P55157 | 16/20 | 0.60 |
| ▸ | SMO | Q99835 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498482 | 0.88 | APOB (0.69) | APOBMTTPSMO | |
| SCHEMBL6499652 | 0.83 | KDR (0.48) | APOBMTTPSMO | |
| SCHEMBL6499757 | 0.81 | APOB (0.41) | APOBMTTPSMOALDH1A1 | |
| SCHEMBL6502746 | 0.80 | SMO (0.48) | APOBMTTPSMONPC1RAB9A | |
| SCHEMBL6500016 | 0.71 | APOB (0.56) | APOBMTTPSMO | |
| SCHEMBL6491556 | 0.71 | APOB (0.48) | APOBMTTPSMO | |
| SCHEMBL6499683 | 0.69 | PTGS2 (0.42) | NPC1RAB9AALDH1A1MAPTNFKB1 | |
| SCHEMBL4785948 | 0.69 | MTTP (1.00) | APOBMTTPSMO | |
| SCHEMBL7038523 | 0.69 | MTTP (1.00) | APOBMTTPSMO | |
| SCHEMBL10205353 | 0.69 | MTTP (1.00) | APOBMTTPSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | APOB 1/4885MTTP 677/4885SMO 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.